Symbols

AVXL

Anavex Life Sciences·NASDAQ

--(--)

AVXL fundamentals

AVXL Q1 2026 Earnings

Anavex Life Sciences (AVXL) released its earnings on Feb 9, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.06 (YoY +57.14%), beat estimates.

Revenue / YoY

EPS / YoY

-0.06

+57.14%

Report date

Feb 9, 2026

AVXL Earnings Call Summary for Q1,2026

Regulatory progress: FDA Type C meeting feedback positive; EMA reexamination of blarcamesine expected to conclude in H1 2026.
Clinical momentum: ACCESS-AD program includes blarcamesine trial with novel biomarkers; AD-006 trial planned for early AD.
Financial strength: $131.7M cash runway; net loss down 46% YoY due to cost optimization.
Strategic initiatives: ANAVEX 3-71 advancing to pivotal trials; Parkinson's, Fragile X, and Rett syndrome programs active.
Key risk: Regulatory uncertainty around ADCS-ADL endpoint sensitivity and CMA confirmatory trial requirements.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Anavex Life Sciences (AVXL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Anavex Life Sciences (AVXL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Anavex Life Sciences (AVXL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Anavex Life Sciences (AVXL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown